NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: A pilot study

Clinical Rheumatology

Volumn 32, Issue 6, 2013, Pages 879-883

  Moraes, Julio C B ^a   Ribeiro, Ana C M ^a   Saad, Carla G S ^a   Lianza, Alessandro C ^a   Silva, Clovis A ^a   Bonfá, Eloísa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ankylosing spondylitis; Anti TNF; Cardiovascular disease; Inflammation; NT proBNP

Indexed keywords

ADALIMUMAB; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEART FUNCTION; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING;

ADULT; BLOOD SEDIMENTATION; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; REGRESSION ANALYSIS; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879197991     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2182-x     Document Type: Article

References (22)

1. Heeneman S, Daemen MJAP (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19:358-362
2. Lautermann D, Braun J (2002) Ankylosing spondylitis - cardiac manifestations. Clin Exp Rheumatol 20:S11-S15
3. Bremander A, Petersson IF, Bergman S, Englund M (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 63:550-556
4. Libby P (2008) Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121:S21-S31
5. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8-17
6. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Eng J Med 350:655-663
7. Provan S, Angel K, Semb AG et al (2010) NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis 69:1946-1950
8. Peters MJL, Welsh P, McInnes IB et al (2010) Tumour necrosis factor α blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 69:1281-1285
9. Armstrong DJ, Gardiner PV, O'Kane MJ (2010) Rheumatoid arthritis patients with active disease and no history of cardiac pathology have higher brain natriuretic peptide (BNP) levels than patients with inactive disease or healthy control subjects. Ulster Med J 79:82-84
10. Jensen J, Ma LP, Fu MLX et al (2010) Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol 99:445-452
11. Meirovich YF, Veinot JP, de Bold MLK et al (2008) Relationship between natriuretic peptides and inflammation: proteomic evidence obtained during acute cellular cardiac allograft rejection in humans. J Heart Lung Transplant 27:31-37
12. Sieper J, Rudwaleit M, Baraliakos X et al (2009) The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:ii1-ii44
13. Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442-452
14. Lipsy RJ (2003) The National Cholesterol Education Program Adult Treatment Panel III guidelines. J Manag Care Pharm 9:2-5
15. Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165-193
16. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Eng J Med 352:666-675
17. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loët X, Pham T (2011) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 78(1):23-30
18. Han C, Robinson DW, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167-2172
19. Ma KK, Ogawa T, Bold AJD (2004) Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 36:505-513
20. de Bold AJ (2009) Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 57:29-32
21. Tsushida K, Tanabe K (2008) Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol 52:212-223
22. Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E (2008) N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from anti-inflammatory drugs: a pilot study. Clin Chem 54:1149-1157 São Paulo São Paulo Development Development